Skip to main content

Organ Transplant Rejection

1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
1 program
1
Sustained Release Injectable TacrolimusPhase 11 trial
Active Trials
NCT03626714Completed8Est. Jan 2019

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Allergy TherapeuticsSustained Release Injectable Tacrolimus

Clinical Trials (1)

Total enrollment: 8 patients across 1 trials

NCT03626714Allergy TherapeuticsSustained Release Injectable Tacrolimus

Safety and Pharmacokinetics of Sustained-release Depot Tacrolimus: A First-in-human Study

Start: Oct 2018Est. completion: Jan 20198 patients
Phase 1Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.